Other & EmergingModerate Evidence

Ds5 Peptide Therapy

Benefits, Side Effects, Cost & Protocols

Ds5 peptide molecular structure diagram from PubChem

DS5 is an investigational peptide being studied for its potential therapeutic applications. Research is ongoing to characterize its mechanism of action and clinical utility.

ByChris Riley(CFA)&Alex Evans, PharmD, MBA(PharmD, MBA)|Updated May 19, 2026

Clinically Reviewed

Reviewed by Alex Evans, PharmD, MBA · Updated May 2026

Evidence-Based

Sourced from FDA, PubMed & ClinicalTrials.gov · View sources

FDA Status

Research Only Not currently approved for human use in the US. Available as a research compound. Not eligible for compounding.

Evidence

Moderate Evidence

Who Is Ds5 Best For?

Research applications3 preclinical studiesLimited human trials or strong preclinical

How Ds5 Works

Mechanisms under investigation.

Ds5 FAQ

What is DS5?

DS5 is an emerging research peptide with limited publicly available data. Research applications are still being explored.

How does DS5 work?

Mechanisms under investigation.

Is DS5 legal to buy?

DS5 is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.

Where can I buy DS5?

DS5 is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.

What category does DS5 belong to?

DS5 is primarily classified as a other & emerging peptide. Miscellaneous and emerging peptides with unique or developing research profiles.

What are the research benefits of DS5?

DS5 has been studied for: Research applications. Limited data; emerging research compound.

Key Studies

89 total on PubMed34 human trials

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results

Martelli M, Ceriani L, Ciccone G et al

J Clin OncolRCT

Omitting radiotherapy in PMBCL with complete metabolic response achieved non-inferior 30-month PFS (96.2% vs 98.5%).

Omitting radiotherapy in PMBCL with complete metabolic response achieved non-inferior 30-month PFS (96.2% vs 98.5%)

Is Telenursing an Effective Method to Control BMI and HbA1c in Illiterate Patients Aged 50 Years and Older With Type 2 Diabetes? A Randomized Controlled Clinical Trial

J Caring SciRCT

Telenursing reduces HbA1c and BMI in older illiterate type 2 diabetes patients.

Telenursing reduces HbA1c and BMI in older illiterate type 2 diabetes patients

Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients

Eertink JJ, Burggraaff CN, Heymans MW et al

Blood Adv · Blood Adv

Interim-PET after 2 or 4 R-CHOP cycles predicts DLBCL prognosis; optimal criteria depend on clinical context

Caries lesions progression in adults: A prospective 2-year cohort study

Abdalla H, Allison PJ, Madathil SA et al

Community Dent Oral Epidemiol · Community Dent Oral Epidemiol

Active caries lesions progress at higher rates than inactive lesions; severity and location predict progression.

Ds5 Compound Data

Molecular Formula

C29H32F6O5

Molecular Weight

574.6 g/mol

IUPAC Name

(4S)-5-[4-[1-ethyl-1-[3-methyl-4-[4,4,4-trifluoro-3-hydroxy-3-(trifluoromethyl)but-1-ynyl]phenyl]propyl]-2-methyl-phenoxy]-4-hydroxy-pentanoic acid

View full compound on PubChem

Medical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. Peptide therapies have not been evaluated by the FDA for most listed indications.All prices shown are estimates based on publicly available data and may not reflect current pricing — providers and brands set their own prices and can change them at any time. Always verify pricing directly with the provider before purchasing. Consult a licensed healthcare provider before starting any peptide protocol.

Ready to explore Ds5 with a provider?

Take our 2-minute quiz to get matched with a board-certified provider specializing in Ds5.

Take the Quiz →